Events

8th Metabolic Continuum Roundtable™ Annual Meeting – More details coming soon
Contact Us »

7th Metabolic Continuum Roundtable™ Annual Meeting – Steatotic Liver Disease (MASLD/MASH): Disease Burden – Patient Reported Outcomes – Health Economics: Payor & Societal Perspectives
November 10, 2023 | Boston, MA
More Information »

6th NASH Roundtable™ Forum – Clinical Trials with Non-Invasive Tests (NITs) Instead of Histology: Fact or Fancy?
November 5, 2022 | Washington, DC
More information »

5th NASH Roundtable™ Virtual Forum – Is Digital Pathology a Game-Changer for Histology for NASH Drug Development?
June 16, 2022 | Virtual
More information »

Resources

Fact Sheet: Metabolic Continuum Roundtable™, leading clinical development experts addressing challenges in NASH drug development

View Fact Sheet »

Member Co-authored Publications

March 5, 2025

MASLD as a non-communicable disease. Read More »

Feburary 20, 2025

EHBP1 suppresses liver fibrosis in metabolic dysfunction-associated steatohepatitis. Read More »

February 18, 2025

Addressing the High and Rising Global Burden of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) and Metabolic Dysfunction-Associated Steatohepatitis (MASH): From the Growing Prevalence to Payors’ Perspective. Read More »

February 15, 2025

Non-invasive evaluation of steatosis and fibrosis in the liver in adult patients living with cystic fibrosis. Read More »

February 11, 2025

The Lipidomic Profile Discriminates Between MASLD and MetALD. Read More »